THERAPY DOSSIER · th-4f27c48a1bdc

5-Methylindole plus tobramycin

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32185144 ↗2020Reported benefit

5-Methylindole Potentiates Aminoglycoside Against Gram-Positive Bacteria Including Persisters Under Hypoionic Conditions.

MouseWoundICRMalen = n = 3 per group in vivoTopical application to the wound120 microlitres of 4 mM 5-methylindole plus 100 micrograms/…Applied immediately after bacterial seeding and absorption

Model: Acute full-thickness skin excision wound (1 cm by 1 cm) on the back, seeded with 5 microlitres of concentrated stationary-phase Staphylococcus aureus including MRSA and CCCP-induced persisters

Tobramycin in pure water killed bacteria more effectively than in saline in vivo (p = 0.011). Addition of 5-methylindole gave only a marginal further gain against stationary-phase cells in vivo but significantly enhanced killing of CCCP-induced persisters (p = 0.012).

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…